Rheumatology

Investigator Dr. John Botson spoke on the phase 4 MIRROR study that supported the FDA approval for pegloticase combined with methotrexate for patients with uncontrolled gout.

John K. Botson MD, RPh, CCD, weighs in on the recent FDA approval of pegloticase injection plus methotrexate for the treatment of uncontrolled gout.

Cancer is linked to many chronic conditions, but what is its relationship with rheumatoid arthritis? Test your knowledge with this quiz.

Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.

Over a 40-year follow-up, approximately one-quarter of the study cohort with juvenile arthritis were reported to have active uveitis.

Higher energy and longer symptom duration at diagnosis were protective factors against medication failure.

New data suggests that a third COVID-19 booster might be warranted in children with juvenile idiopathic arthritis.

According to preliminary data, patients with JIA experience the same safety and immunogenicity as healthy individuals when vaccinated with the Pfizer COVID-19 vaccine.

Iwasaki and her team analyzed 3220 unique sequences of endogenous retroviruses that are a part of the human genetic make up or genome to understand if retroviruses cause or worsen this disease.

Data suggests baricitinib not only significantly reduced the time to flares but also the frequency of flares in patients with JIA when compared with placebo.

A high percentage of pediatric patients with JIA do not achieve inactive disease during the first 2 years following diagnosis.

A new study revealed no significant relationship between patients with juvenile idiopathic arthritis and exposure to maternal infection, however, investigators said that suggestive evidence of differential sex-specific results indicate a need for further study.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of his study that examined the variables associated with achieving minimal disease activity in patients with recent-onset psoriatic arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 9, 2022.

Expert Michael Aziz discusses clinical complications that patients face when they become pregnant as well as the importance of medication management and abortion care.

The decision was based on results from the MIRROR trial, which evaluated the concomitant use of pegloticase with methotrexate.

The French national healthcare database (SNDS) was used to evaluate malignancy between patients with RA initiating bDMARDs and those continuing csDMARDs.

David Felson, MD, MPH, discusses his recent study, “Meaning of patient global assessment when joint counts are low in rheumatoid arthritis.”

In the prospective, open-labeled trial, patients were randomly assigned to receive either low-dose benzbromarone or low-dose febuxostat for 12 weeks.

Previous attempts to make associations between JIA and prenatal maternal infection is difficult due to the rarity of JIA diagnosis and recall bias.

Many people now use activity trackers to assess their activity levels, but what role can these devices play in managing rheumatoid arthritis patients? Test your knowledge with this quiz.

Dr. Philip Mease explains that it's a good time to be treating psoriatic arthritis after results from a clinical trial show that guselkumab provided continuous improvement across measures of health-related quality of life.

Results of a proof-of-concept trial suggest early intervention with methotrexate could alter the disease course and improve symptoms in patients with arthralgia at risk of progressing to rheumatoid arthritis

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2022.

With guselkumab, patients with active psoriatic arthritis achieved efficacy that was sustained through a 2 year clinical trial. Results show that the treatment offered continuous improvement across measures of health-related quality of life.

“The differential contribution of IL-6 and IL-17 pathways to the pathogenesis of psoriatic arthritis is not fully understood,” investigators stated.

Take a few minutes to check out Rheumatology Network's top expert interviews from Q2 2022.

The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases.

The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.

Take a few minutes to discover Rheumatology Network's most-viewed EULAR 2022 coverage.